Novavax, Inc., a biotechnology company to develop and commercializing next-gen vaccines for serious infectious diseases, announced that the Novavax Covid-19 vaccine has received emergency use authorization (EUA) from the Food and Drug Administration (FDA) of the United States.
The approval is given to provide a two-dose primary series for active immunization to prevent COVID-19 disease caused by serious acute respiratory syndrome in individuals over 18 years of age.
Stanley C. Erck, CEO and president of Novavax, said the emergency use authorization by the US FDA of their COVID-19 vaccine provides the country with access to the very first COVID-19 vaccine.
He also said this approval reflects the strength of the efficacy and safety data of their COVID-19 vaccine, and it also highlights the critical need to offer another vaccine option for the people of the United States while the COVID-19 pandemic continues.
Karen Kotloff, professor of paediatrics at the University Of Maryland School Of Medicine, said providers and patients in the United States now have access to a protein-based COVID-19 vaccine, that is backed by data that has demonstrated safety, efficacy, and tolerability.
He added that offering more vaccine technologies and options in their vaccination portfolio, including those vaccines built upon technologies that have been used successfully for years, will hopefully help to increase their COVID-19 vaccination rate in the United States.
